According to the company, AML program has the potential to produce multiple drug candidates with differing activity profiles that can be used to treat acute leukemias with different gene mutation profiles.
COTI plans to pursue licensing opportunities based upon the scientific results of the program and will introduce the AML program to prospective partners.
COTI’s AML program is protected by a number of issued American, European and Canadian patents.
COTI CEO Wayne Danter said that successful candidates from this program will provide additional valuable commercial assets that can be licensed to partners for further development.
"The successful synthesis and initiation of the preclinical evaluation of the first candidates from our program provides further validation of CHEMSAS as a powerful artificial intelligence drug discovery engine," Danter added.